On the eve of Forest Laboratories' proxy vote, activist investor Carl Icahn is still campaigning. After accusing Forest's board of cronyism and lethargy, after critiquing CEO Howard Solomon's performance--and his son's résumé--Icahn is taking the company to task for a recent FDA warning letter. Not only was the letter itself worrisome, Icahn said, but Forest didn't disclose it in a recent quarterly filing with the Securities and Exchange Commission. Story
Like what you're reading?
Click here to get more news like this delivered to your inbox everyday>>